- Author: Thomas E Herchline, MD; Chief Editor: Michael Stuart Bronze, MD more...
Tuberculosis (TB) (see the image below), a multisystemic disease with myriad presentations and manifestations, is the most common cause of infectious disease–related mortality worldwide. Although TB rates are decreasing in the United States, the disease is becoming more common in many parts of the world. In addition, the prevalence of drug-resistant TB is increasing worldwide.
See 11 Travel Diseases to Consider Before and After the Trip, a Critical Images slideshow, to help identify and manage infectious travel diseases.
Signs and symptoms
Classic clinical features associated with active pulmonary TB are as follows (elderly individuals with TB may not display typical signs and symptoms):
Chest pain (can also result from tuberculous acute pericarditis)
Symptoms of tuberculous meningitis may include the following:
Headache that has been either intermittent or persistent for 2-3 weeks
Subtle mental status changes that may progress to coma over a period of days to weeks
Low-grade or absent fever
Symptoms of skeletal TB may include the following:
Back pain or stiffness
Lower-extremity paralysis, in as many as half of patients with undiagnosed Pott disease
Tuberculous arthritis, usually involving only 1 joint (most often the hip or knee, followed by the ankle, elbow, wrist, and shoulder)
Symptoms of genitourinary TB may include the following:
In men, a painful scrotal mass, prostatitis, orchitis, or epididymitis
In women, symptoms mimicking pelvic inflammatory disease
Symptoms of gastrointestinal TB are referable to the infected site and may include the following:
Nonhealing ulcers of the mouth or anus
Difficulty swallowing (with esophageal disease)
Abdominal pain mimicking peptic ulcer disease (with gastric or duodenal infection)
Malabsorption (with infection of the small intestine)
Pain, diarrhea, or hematochezia (with infection of the colon)
Physical examination findings associated with TB depend on the organs involved. Patients with pulmonary TB may have the following:
Abnormal breath sounds, especially over the upper lobes or involved areas
Rales or bronchial breath signs, indicating lung consolidation
Signs of extrapulmonary TB differ according to the tissues involved and may include the following:
The absence of any significant physical findings does not exclude active TB. Classic symptoms are often absent in high-risk patients, particularly those who are immunocompromised or elderly.
See Clinical Presentation for more detail.
Screening methods for TB include the following:
In vitro blood test based on interferon gamma release assay (IGRA) with antigens specific for Mycobacterium tuberculosis for latent infection
Obtain the following laboratory tests for patients with suspected TB:
Acid-fast bacilli (AFB) smear and culture using sputum obtained from the patient: Absence of a positive smear result does not exclude active TB infection; AFB culture is the most specific test for TB
HIV serology in all patients with TB and unknown HIV status: Individuals infected with HIV are at increased risk for TB
Other diagnostic testing may warrant consideration, including the following:
Specific enzyme-linked immunospot (ELISpot)
Nucleic acid amplification tests
Positive cultures should be followed by drug susceptibility testing; symptoms and radiographic findings do not differentiate multidrug-resistant TB (MDR-TB) from fully susceptible TB. Such testing may include the following:
Direct DNA sequencing analysis
Automated molecular testing
Microscopic-observation drug susceptibility (MODS) and thin-layer agar (TLA) assays
Additional rapid tests (eg, BACTEC-460, ligase chain reaction, luciferase reporter assays, FASTPlaque TB-RIF)
Obtain a chest radiograph to evaluate for possible associated pulmonary findings. The following patterns may be seen:
Cavity formation: Indicates advanced infection; associated with a high bacterial load
Noncalcified round infiltrates: May be confused with lung carcinoma
Homogeneously calcified nodules (usually 5-20 mm): Tuberculomas, representing old infection
Primary TB: Typically, pneumonialike picture of infiltrative process in middle or lower lung regions
Reactivation TB: Pulmonary lesions in posterior segment of right upper lobe, apicoposterior segment of left upper lobe, and apical segments of lower lobes
TB associated with HIV disease: Frequently atypical lesions or normal chest radiographic findings
Healed and latent TB: Dense pulmonary nodules in hilar or upper lobes; smaller nodules in upper lobes
Miliary TB: Numerous small, nodular lesions that resemble millet seeds
Pleural TB: Empyema may be present, with associated pleural effusions
Workup considerations for extrapulmonary TB include the following:
Biopsy of bone marrow, liver, or blood cultures
If tuberculous meningitis or tuberculoma is suspected, perform lumbar puncture
If vertebral ( Pott disease) or brain involvement is suspected, CT or MRI is necessary
If genitourinary complaints are reported, urinalysis and urine cultures can be obtained
See Workup for more detail.
Physical measures (if possible or practical) include the following:
Isolate patients with possible TB in a private room with negative pressure
Have medical staff wear high-efficiency disposable masks sufficient to filter the bacillus
Continue isolation until sputum smears are negative for 3 consecutive determinations (usually after approximately 2-4 weeks of treatment)
Initial empiric pharmacologic therapy consists of the following 4-drug regimens:
Either ethambutol or streptomycin 
Special considerations for drug therapy in pregnant women include the following:
In the United States, pyrazinamide is reserved for women with suspected MDR-TB
Streptomycin should not be used
Preventive treatment is recommended during pregnancy
Pregnant women are at increased risk for isoniazid-induced hepatotoxicity
Breastfeeding can be continued during preventive therapy
Special considerations for drug therapy in children include the following:
Most children with TB can be treated with isoniazid and rifampin for 6 months, along with pyrazinamide for the first 2 months if the culture from the source case is fully susceptible.
For postnatal TB, the treatment duration may be increased to 9 or 12 months
Ethambutol is often avoided in young children
Special considerations for drug therapy in HIV-infected patients include the following:
Dose adjustments may be necessary [2, 3]
Rifampin must be avoided in patients receiving protease inhibitors; rifabutin may be substituted
Considerations in patients receiving antiretroviral therapy include the following:
Patients with HIV and TB may develop a paradoxical response when starting antiretroviral therapy
Starting antiretroviral therapy early (eg, < 4 weeks after the start of TB treatment) may reduce progression to AIDS and death 
In patients with higher CD4+ T-cell counts, it may be reasonable to defer antiretroviral therapy until the continuation phase of TB treatment 
When MDR-TB is suspected, start treatment empirically before culture results become available, then modify the regimen as necessary. Never add a single new drug to a failing regimen. Administer at least 3 (preferably 4-5) of the following medications, according to drug susceptibilities:
An aminoglycoside: Streptomycin, amikacin, capreomycin, kanamycin
A fluoroquinolone: Levofloxacin (best suited over the long term), ciprofloxacin, ofloxacin
A thioamide: Ethionamide, prothionamide
Rifabutin as a substitute for rifampin
A diarylquinoline: Bedaquiline
Surgical resection is recommended for patients with MDR-TB whose prognosis with medical treatment is poor. Procedures include the following:
Segmentectomy (rarely used)
Pleurectomy for thick pleural peel (rarely indicated)
Recommended regimens for isoniazid and rifampin for latent TB have been published by the US Centers for Disease Control and Prevention (CDC) : An alternative regimen for latent TB is isoniazid plus rifapentine as directly observed therapy (DOT) once-weekly for 12 weeks[7, 8] ; it is not recommended for children under 2 years, pregnant women or women planning to become pregnant, or patients with TB infection presumed to result from exposure to a person with TB that is resistant to 1 of the 2 drugs.
Tuberculosis (TB), a multisystemic disease with myriad presentations and manifestations, is the most common cause of infectious disease–related mortality worldwide. The World Health Organization (WHO) has estimated that 2 billion people have latent TB and that globally, in 2009, the disease killed 1.7 million people. (See Epidemiology.)
Although TB rates are decreasing in the United States, the disease is becoming more common in many parts of the world. In addition, the prevalence of drug-resistant TB is also increasing worldwide. Coinfection with the human immunodeficiency virus (HIV) has been an important factor in the emergence and spread of resistance. (See Treatment.)
Mycobacterium tuberculosis, a tubercle bacillus, is the causative agent of TB. It belongs to a group of closely related organisms—including M africanum, M bovis, and M microti —in the M tuberculosis complex. (See Etiology.) An image of the bacterium is seen below.
The lungs are the most common site for the development of TB; 85% of patients with TB present with pulmonary complaints. Extrapulmonary TB can occur as part of a primary or late, generalized infection. (See Pathophysiology and Presentation.)
The primary screening method for TB infection (active or latent) is the Mantoux tuberculin skin test with purified protein derivative (PPD). An in vitro blood test based on interferon-gamma release assay (IGRA) with antigens specific for M tuberculosis can also be used to screen for latent TB infection. Patients suspected of having TB should submit sputum for acid-fast bacilli (AFB) smear and culture. (See Workup.)
The usual treatment regimen for TB cases from fully susceptible M tuberculosis isolates consists of 6 months of multidrug therapy. Empiric treatment starts with a 4-drug regimen of isoniazid, rifampin, pyrazinamide, and either ethambutol or streptomycin; this therapy is subsequently adjusted according to susceptibility testing results and toxicity. Pregnant women, children, HIV-infected patients, and patients infected with drug-resistant strains require different regimens. (See Treatment and Medication.)
Laws vary from state to state, but communicable-disease laws typically empower public health officials to investigate suspected cases of TB, including potential contacts of persons with TB. In addition, patients may be incarcerated for noncompliance with therapy.
New TB treatments are being developed, and new TB vaccines are under investigation. (See Epidemiology and Treatment.)
TB is an ancient disease. Signs of skeletal TB (Pott disease) have been found in remains from Europe from Neolithic times (8000 BCE), ancient Egypt (1000 BCE), and the pre-Columbian New World. TB was recognized as a contagious disease by the time of Hippocrates (400 BCE), when it was termed "phthisis" (Greek from phthinein, to waste away). In English, pulmonary TB was long known by the term “consumption.” German physician Robert Koch discovered and isolated M tuberculosis in 1882.
The worldwide incidence of TB increased with population density and urban development, so that by the Industrial Revolution in Europe (1750), it was responsible for more than 25% of adult deaths. In the early 20th century, TB was the leading cause of death in the United States; during this period, however, the incidence of TB began to decline because of various factors, including the use of basic infection-control practices (eg, isolation).
Resurgence of TB
The US Centers for Disease Control and Prevention (CDC) has been recording detailed epidemiologic information on TB since 1953. Beginning in 1985, a resurgence of TB was noted. The increase was observed primarily in ethnic minorities and especially in persons infected with HIV. TB control programs were revamped and strengthened across the United States, and rates again began to fall. (See Epidemiology.)
As an AIDS (acquired immunodeficiency syndrome)–related opportunistic infection, TB is associated with HIV infections, with dual infections being frequently noted. Globally, coinfection with HIV is highest in South Africa, India, and Nigeria. Persons with AIDS are 20-40 times more likely than immunocompetent persons to develop active TB. Correspondingly, TB is the leading cause of mortality among persons infected with HIV.
Worldwide, TB is most common in Africa, the West Pacific, and Eastern Europe. These regions are plagued with factors that contribute to the spread of TB, including the presence of limited resources, HIV infection, and multidrug-resistant (MDR) TB. (See Epidemiology.)
MDR-TB is defined as resistance to isoniazid and rifampin, which are the 2 most effective first-line drugs for TB. In 2006, an international survey found that 20% of M tuberculosis isolates were MDR. A rare type of MDR-TB, called extensively drug-resistant TB (XDR-TB), is resistant to isoniazid, rifampin, any fluoroquinolone, and at least one of 3 injectable second-line drugs (ie, amikacin, kanamycin, or capreomycin). XDR-TB resistant to all anti-TB drugs tested has been reported in Italy, Iran, and India.
Multiple factors contribute to the drug resistance of M tuberculosis, including incomplete and inadequate treatment or adherence to treatment, logistical issues, virulence of the organism, multidrug transporters, host genetic factors, and HIV infection. A study from South Africa found high genotypic diversity and geographic distribution of XDR-TB isolates, suggesting that acquisition of resistance, rather than transmission, accounts for between 63% and 75% of XDR-TB cases.
In a 2008 report by the WHO, the proportion of TB cases in which the patient was resistant to at least 1 antituberculosis drug varied widely among different regions of the world, ranging from 0% to over 50%; the proportion of MDR-TB cases ranged from 0% to over 20%. The WHO calculated that the global population-weighted proportion of MDR-TB was 2.9% in new TB cases, 15.3% in previously treated patients, and 5.3% in all TB cases.
In the United States, the percentage of MDR-TB cases has increased slowly, from 0.9% of the total number of reported TB cases in 2008 to 1.3% of cases in 2011. Although the percentage of US-born patients with primary MDR-TB has remained below 1% since 1997, the proportion of cases in which the patient was foreign born increased from 25.3% in 1993 to 82.7% in 2011.
XDR-TB is becoming increasingly significant. According to the US National TB Surveillance System (NTSS), between 1993 and 2006 a total of 49 cases (3% of evaluable MDR-TB cases) met the revised case definition for XDR-TB. The largest number of XDR-TB cases was found in New York City and California.
The cure rate in persons with MDR-TB is 50-60%, compared with 95-97% for persons with drug-susceptible TB. The estimated cure rate for XDR-TB is 30-50%. In people who are also infected with HIV, MDR-TB and XDR-TB often produce fulminant and fatal disease; time from TB exposure to death averages 2-7 months. In addition, these cases are highly infectious, with conversion rates of as much as 50% in exposed health-care workers.
Global surveillance and treatment of TB
As previously stated, multidrug resistance has been driven by poor compliance with TB therapies , resulting in difficulties in controlling the disease. Consequently, a threat of global pandemic occurred in the late 1980s and early 1990s. Reacting to these signals, the WHO developed a plan to try to identify 70% of the world's cases of TB and to completely treat at least 85% of these cases by the year 2000.
Out of these goals were born major TB surveillance programs and the concept of directly observed therapy (DOT), which requires a third party to witness compliance with pharmacotherapy. With worldwide efforts, global detection of smear-positive cases rose from 11% (1991) to 45% (2003), with 71-89% of those cases undergoing complete treatment.
Approach to TB in the emergency department
Despite the importance of early isolation of patients with active TB, a standardized triage protocol with acceptable sensitivities has yet to be developed. Moran et al demonstrated that among patients with active TB in the emergency department (ED), TB was often unsuspected, and isolation measures were not used. The difficulty in establishing such a protocol only highlights the importance of the emergency physician’s role in the prompt identification and isolation of active TB.
A large percentage of ED patients are at increased risk for having active TB, including homeless/shelter-dwelling patients, travelers from endemic areas, immunocompromised patients, health-care workers, and incarcerated patients. Therefore, emergency physicians must consider the management and treatment of TB as a critical public health measure in the prevention of a new epidemic.
For high-risk cases, prehospital workers can assist in identifying household contacts who may also be infected or who may be at high risk of becoming infected.
Prehospital workers should be aware that any case of active TB in a young child indicates disease in 1 or more adults with close contact, usually within the same household. TB in a child is a sentinel event indicating recent transmission.
Extrapulmonary involvement in TB
Extrapulmonary involvement occurs in one fifth of all TB cases; 60% of patients with extrapulmonary manifestations of TB have no evidence of pulmonary infection on chest radiographs or in sputum cultures.
The incidence of cutaneous TB appears low. In areas such as India or China, where TB prevalence is high, cutaneous manifestations of TB (overt infection or the presence of tuberculids) have been found in less than 0.1% of individuals seen in dermatology clinics.
TB can affect any structure in the eye and typically presents as a granulomatous process. Keratitis, iridocyclitis, intermediate uveitis, retinitis, scleritis, and orbital abscess are within the spectrum of ocular disease. Choroidal tubercles and choroiditis are the most common ocular presentations of TB. Adnexal or orbital disease may be seen with preauricular lymphadenopathy. Because of the wide variability in the disease process, presenting complaints will vary.
Most often, patients will complain of blurry vision that may or may not be associated with pain and red eye. In the rare case of orbital disease, proptosis, double vision, or extraocular muscle motility restriction may be the presenting complaint. Preseptal cellulitis in children with spontaneous draining fistula may also occur. In cases of both pulmonary and extrapulmonary TB, there may be ocular findings without ocular complaints.
In patients with confirmed active pulmonary or active, nonocular extrapulmonary TB, ocular incidence ranges from 1.4-5.74%. In HIV patients, the incidence of ocular TB may be higher, with a reported prevalence of from 2.8-11.4%.
Patient information on TB can be found at the following sites:
World Health Organization Tuberculosis
Infection with M tuberculosis results most commonly through exposure of the lungs or mucous membranes to infected aerosols. Droplets in these aerosols are 1-5 μm in diameter; in a person with active pulmonary TB, a single cough can generate 3000 infective droplets, with as few as 10 bacilli needed to initiate infection.
When inhaled, droplet nuclei are deposited within the terminal airspaces of the lung. The organisms grow for 2-12 weeks, until they reach 1000-10,000 in number, which is sufficient to elicit a cellular immune response that can be detected by a reaction to the tuberculin skin test.
Mycobacteria are highly antigenic, and they promote a vigorous, nonspecific immune response. Their antigenicity is due to multiple cell wall constituents, including glycoproteins, phospholipids, and wax D, which activate Langerhans cells, lymphocytes, and polymorphonuclear leukocytes
When a person is infected with M tuberculosis, the infection can take 1 of a variety of paths, most of which do not lead to actual TB. The infection may be cleared by the host immune system or suppressed into an inactive form called latent tuberculosis infection (LTBI), with resistant hosts controlling mycobacterial growth at distant foci before the development of active disease. Patients with LTBI cannot spread TB.
The lungs are the most common site for the development of TB; 85% of patients with TB present with pulmonary complaints. Extrapulmonary TB can occur as part of a primary or late, generalized infection. An extrapulmonary location may also serve as a reactivation site; extrapulmonary reactivation may coexist with pulmonary reactivation.
The most common sites of extrapulmonary disease are as follows (the pathology of these lesions is similar to that of pulmonary lesions):
Mediastinal, retroperitoneal, and cervical (scrofula) lymph nodes - The most common site of tuberculous lymphadenitis (scrofula) is in the neck, along the sternocleidomastoid muscle; it is usually unilateral and causes little or no pain; advanced cases of tuberculous lymphadenitis may suppurate and form a draining sinus
Infected end organs typically have high regional oxygen tension (as in the kidneys, bones, meninges, eyes, and choroids, and in the apices of the lungs). The principal cause of tissue destruction from M tuberculosis infection is related to the organism's ability to incite intense host immune reactions to antigenic cell wall proteins.
Uveitis caused by TB is the local inflammatory manifestation of a previously acquired primary systemic tubercular infection. There is some debate with regard to whether molecular mimicry, as well as a nonspecific response to noninfectious tubercular antigens, provides a mechanism for active ocular inflammation in the absence of bacterial replication.
The typical TB lesion is an epithelioid granuloma with central caseation necrosis. The most common site of the primary lesion is within alveolar macrophages in subpleural regions of the lung. Bacilli proliferate locally and spread through the lymphatics to a hilar node, forming the Ghon complex.
Early tubercles are spherical, 0.5- to 3-mm nodules with 3 or 4 cellular zones demonstrating the following features:
A central caseation necrosis
An inner cellular zone of epithelioid macrophages and Langhans giant cells admixed with lymphocytes
An outer cellular zone of lymphocytes, plasma cells, and immature macrophages
A rim of fibrosis (in healing lesions)
Initial lesions may heal and the infection become latent before symptomatic disease occurs. Smaller tubercles may resolve completely. Fibrosis occurs when hydrolytic enzymes dissolve tubercles and larger lesions are surrounded by a fibrous capsule. Such fibrocaseous nodules usually contain viable mycobacteria and are potential lifelong foci for reactivation or cavitation. Some nodules calcify or ossify and are seen easily on chest radiographs.
Tissues within areas of caseation necrosis have high levels of fatty acids, low pH, and low oxygen tension, all of which inhibit growth of the tubercle bacillus.
If the host is unable to arrest the initial infection, the patient develops progressive, primary TB with tuberculous pneumonia in the lower and middle lobes of the lung. Purulent exudates with large numbers of acid-fast bacilli can be found in sputum and tissue. Subserosal granulomas may rupture into the pleural or pericardial spaces and create serous inflammation and effusions.
With the onset of the host immune response, lesions that develop around mycobacterial foci can be either proliferative or exudative. Both types of lesions develop in the same host, since infective dose and local immunity vary from site to site.
Proliferative lesions develop where the bacillary load is small and host cellular immune responses dominate. These tubercles are compact, with activated macrophages admixed, and are surrounded by proliferating lymphocytes, plasma cells, and an outer rim of fibrosis. Intracellular killing of mycobacteria is effective, and the bacillary load remains low.
Exudative lesions predominate when large numbers of bacilli are present and host defenses are weak. These loose aggregates of immature macrophages, neutrophils, fibrin, and caseation necrosis are sites of mycobacterial growth. Without treatment, these lesions progress and infection spreads.
TB is caused by M tuberculosis, a slow-growing obligate aerobe and a facultative intracellular parasite. The organism grows in parallel groups called cords (as seen in the image below). It retains many stains after decoloration with acid-alcohol, which is the basis of the acid-fast stains used for pathologic identification.
Mycobacteria, such as M tuberculosis, are aerobic, non–spore-forming, nonmotile, facultative, curved intracellular rods measuring 0.2-0.5 μm by 2-4 μm. Their cell walls contain mycolic, acid-rich, long-chain glycolipids and phospholipoglycans (mycocides) that protect mycobacteria from cell lysosomal attack and also retain red basic fuchsin dye after acid rinsing (acid-fast stain).
Humans are the only known reservoir for M tuberculosis. The organism is spread primarily as an airborne aerosol from an individual who is in the infectious stage of TB (although transdermal and GI transmission have been reported).
In immunocompetent individuals, exposure to M tuberculosis usually results in a latent/dormant infection. Only about 5% of these individuals later show evidence of clinical disease. Alterations in the host immune system that lead to decreased immune effectiveness can allow M tuberculosis organisms to reactivate, with tubercular disease resulting from a combination of direct effects from the replicating infectious organism and from subsequent inappropriate host immune responses to tubercular antigens.
Molecular typing of M tuberculosis isolates in the United States by restriction fragment-length polymorphism analysis suggests more than one third of new patient occurrences of TB result from person-to-person transmission. The remainder results from reactivation of latent infection.
Verhagen et al demonstrated that large clusters of TB are associated with an increased number of tuberculin skin test–positive contacts, even after adjusting for other risk factors for transmission. The number of positive contacts was significantly lower for index cases with isoniazid-resistant TB compared with index cases with fully-susceptible TB. This suggests that some TB strains may be more transmissible than other strains and that isoniazid resistance is associated with lower transmissibility.
Because of the ability of M tuberculosis to survive and proliferate within mononuclear phagocytes, which ingest the bacterium, M tuberculosis is able to invade local lymph nodes and spread to extrapulmonary sites, such as the bone marrow, liver, spleen, kidneys, bones, and brain, usually via hematogenous routes.
Although mycobacteria are spread by blood throughout the body during initial infection, primary extrapulmonary disease is rare except in immunocompromised hosts. Infants, older persons, or otherwise immunosuppressed hosts are unable to control mycobacterial growth and develop disseminated (primary miliary) TB. Patients who become immunocompromised months to years after primary infection also can develop late, generalized disease.
The following factors help to determine whether a TB infection is likely to be transmitted:
Number of organisms expelled
Concentration of organisms
Length of exposure time to contaminated air
Immune status of the exposed individual
Infected persons living in crowded or closed environments pose a particular risk to noninfected persons. Approximately 20% of household contacts develop infection (positive tuberculin skin test). Microepidemics have occurred in closed environments such as submarines and on transcontinental flights. Populations at high risk for acquiring the infection also include hospital employees, inner-city residents, nursing home residents, and prisoners.
The following factors increase an individual’s risk of acquiring active tuberculosis:
Intravenous (IV) drug abuse
Diabetes mellitus (3-fold risk increase)
Tumor necrosis factor–alpha (TNF-α) antagonists
Cancer of the head and neck
End-stage renal disease
Intestinal bypass surgery or gastrectomy
Chronic malabsorption syndromes
Smoking - Smokers who develop TB should be encouraged to stop smoking to decrease the risk of relapse 
Age below 5 years
TNF antagonists and steroids
Treatment with tumor necrosis factor–alpha (TNF-α) antagonists, which is used for rheumatoid arthritis, psoriasis, and several other autoimmune disorders, has been associated with a significantly increased risk for TB. Reports have included atypical presentations, extrapulmonary and disseminated disease, and deaths. Patients scheduled to begin therapy with a TNF-α antagonist should be screened for latent TB and counseled regarding the risk of TB.
Immunosuppressive therapy includes long-term administration of systemic steroids (prednisone or its equivalent, given >15 mg/day for ≥4 wk or more) and/or inhaled steroids. Brassard and colleagues reported that inhaled steroids, in the absence of systemic steroids, were associated with a relative risk of 1.5 for TB.
TB in children
In children younger than 5 years, the potential for development of fatal miliary TB or meningeal TB is a significant concern. Osteoporosis, sclerosis, and bone involvement are more common in children with TB than in adults with the disease. The epiphyseal bones can be involved because of their high vascularity.
Children do not commonly infect other children, because they rarely develop cough and their sputum production is scant. However, cases of child-child and child-adult TB transmission are well documented. (See Pediatric Tuberculosis for complete information on this topic.)
The genetics of tuberculosis are quite complex, involving many genes. Some of those genes involve important aspects of the immune system, while others involve more specific mechanisms by which the human body interacts with mycobacterium species. The genes that follow have polymorphisms that are associated with either susceptibility to or protection from tuberculosis. Additionally, regions such as 8q12-q13 are associated with increased risk, although an exact mechanism or candidate gene has not yet been found.
In a study from Africa, 4 different polymorphisms of the NRAMP1 gene were associated with an increased risk for TB. Subjects who possessed a certain 2 of those polymorphisms (located in an intron and in a region upstream from the coding region) were at particular risk for contracting TB. The association of NRAMP1 with risk of TB has been replicated in subsequent studies.[28, 29]
The product of this gene interacts with the interferon system and as such is an important aspect of the immune response. A study of 27 different polymorphisms in this gene found 3 that were associated with increased risk of TB; 2 of these polymorphisms were intronic and the third was a missense mutation in exon 11.
The product of this gene functions to suppress cytokine signaling, which is important for inflammatory signaling. One study found that a single-nucleotide polymorphism upstream from CISH was associated with susceptibility to TB, malaria, and invasive bacterial disease. The same study found that leukocytes of persons who had the risk variant for CISH had a decreased response to interleukin 2.
The expression of this gene is induced by interferon, and the product is involved in the control of intracellular mycobacteria. One study found that homozygosity for a particular polymorphism in the promoter region of IRGM confers protection against TB, but only in persons of European ancestry. In vitro analyses showed increased expression of the IRGM gene product with the promoter variant, further underscoring the importance of this gene in the immune response to mycobacterial infection.
Interferon gamma is a cytokine that has an important role in the immune response to intracellular infections, including viral and mycobacterial infections. One particular polymorphism near a microsatellite in this gene is associated with increased expression of the IFNG gene and increased production of interferon gamma. An association study found evidence that this polymorphism was related to protection against TB.
The product of IFNGR1 is part of a heterodimeric receptor for interferon gamma. This has important implications for the response of this part of the immune system in the defense against certain infections.
A region of homozygosity in the region of the IFNGR1 gene has been found in a group of related children in southern Europe who were known to have a predisposition to mycobacterial infection; this predisposition, which had resulted in death in three children and chronic mycobacterial infection in a fourth, was felt to be autosomal recessive. Subsequent sequencing of the gene showed a nonsense mutation that resulted in a nonfunctional gene product.
The TIRAP gene produces a protein that has several functions in the immune system. A study of 33 polymorphisms in the TIRAP gene found that heterozygosity for a serine-to-leucine substitution was associated with protection again invasive pneumococcal disease, bacteremia, malaria, and TB.
The product of the CD209 gene is involved in the function of dendritic cells, which are involved in the capture of certain microorganisms. An association was found between susceptibility to TB and a polymorphism upstream from the CD209 gene in a multiracial South African population.
Occurrence in the United States
With the improvement of living conditions and the introduction of effective treatment (streptomycin) in the late 1940s, the number of patients in the United States reported to have TB began to steadily decline (126,000 TB patients in 1944; 84,000 in 1953; 22,000 in 1984; 14,000 in 2004), despite explosive growth in the total population (140 million people in 1946, 185 million in 1960, 226 million in 1980).
On a national level, the incidence of TB is at an all-time low. Since the 1992 TB resurgence peak in the United States, the number of TB cases reported annually has decreased by 61%.
In 2011, 10,528 TB cases (a rate of 3.4 cases per 100,000 population) were reported in the United States, representing a 5.8% decline in the number of reported TB cases and a 6.4% decline in the case rate, compared with 2010.
California, New York, Texas, and Florida accounted for half of all TB cases reported in the United States in 2011. Cases in foreign-born persons made up 62% of the national case total; foreign-born Hispanics and Asians together represented 80% of TB cases in foreign-born persons and accounted for 50% of the national case total. The top five countries of origin for foreign-born persons with TB were Mexico, the Philippines, India, Vietnam, and China.
Among racial and ethnic groups, the largest percentage of total cases was in Asians (30%), followed by Hispanics (29%) and non-Hispanic blacks/African Americans (15%). However, blacks/African Americans represented 39% of TB cases in US-born persons.
There were 529 deaths from TB in 2009, the most recent year for which these data are available.
Globally, more than 1 in 3 individuals is infected with TB. According to the WHO, there were 8.8 million incident cases of TB worldwide in 2010, with 1.1 million deaths from TB among HIV-negative persons and an additional 0.35 million deaths from HIV-associated TB. In 2009, almost 10 million children were orphaned as a result of parental deaths caused by TB.
Overall, the WHO noted the following :
The absolute number of TB cases has been falling since 2006 (rather than rising slowly, as indicated in previous global reports)
TB incidence rates have been falling since 2002 (2 years earlier than previously suggested)
Estimates of the number of deaths from TB each year have been revised downwards
The 5 countries with the highest number of incident cases in 2010 were India, China, South Africa, Indonesia, and Pakistan. India alone accounted for an estimated 26% of all TB cases worldwide, and China and India together accounted for 38%.
In 2011, only 16% of TB cases in the US occurred in non-Hispanic whites; 84% occurred in racial and ethnic minorities, as follows :
Hispanics - 29%
Asians - 30%
Non-Hispanic blacks/African Americans - 23%
American Indians/native Alaskans - 1%
Native Hawaiians/other Pacific Islanders – 1%
However, race is not clearly an independent risk factor, as foreign-born persons account for 77% of TB cases among Hispanics and 96% of TB cases among Asians, but only 29% of TB cases among blacks. This skewed distribution is most likely due to socioeconomic factors.
Despite the fact that TB rates have declined in both sexes in the United States, certain differences exist. TB rates in women have declined with age, but in men, rates have increased with age. In addition, men are more likely than women to have a positive tuberculin skin test result. The reason for these differences may be social, rather than biologic, in nature.
The estimated sex prevalence for TB varies by source, from no sex prevalence to a male-to-female ratio in the United States of 2:1.
Higher rates of TB infection are seen in young, nonwhite adults (peak incidence, 25-40 y) than in white adults. In addition, white adults manifest the disease later (peak incidence, age 70 y) than do nonwhite persons.
In the United States, more than 60% of TB cases occur in persons aged 25-64 years; however, the age-specific risk is highest in persons older than 65 years. TB is uncommon in children aged 5-15 years.
Full resolution is generally expected with few complications in cases of non-MDR- and non-XDR-TB, when the drug regimen is completed. Among published studies involving DOT treatment of TB, the rate of recurrence ranges from 0-14%. In countries with low TB rates, recurrences usually occur within 12 months of treatment completion and are due to relapse. In countries with higher TB rates, most recurrences after appropriate treatment are probably due to reinfection rather than relapse.
Poor prognostic markers include extrapulmonary involvement, an immunocompromised state, older age, and a history of previous treatment. In a prospective study of 199 patients with TB in Malawi, 12 (6%) died. Risk factors for dying were reduced baseline TNF-α response to stimulation (with heat-killed M tuberculosis), low body mass index, and elevated respiratory rate at TB diagnosis.
[Guideline] Treatment of tuberculosis. MMWR Recomm Rep. 2003 Jun 20. 52:1-77. [Medline].
Swaminathan S, Narendran G, Venkatesan P, et al. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med. 2010 Apr 1. 181(7):743-51. [Medline].
Centers for Disease Control and Prevention. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis. CDC. Available at http://www.cdc.gov/tb/TB_HIV_Drugs/default.htm. Accessed: 08/20/2008.
Torok ME, Farrar JJ. When to start antiretroviral therapy in HIV-associated tuberculosis. N Engl J Med. 2011 Oct 20. 365(16):1538-40. [Medline].
Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep. 2000 Jun 9. 49:1-51. [Medline].
CDC. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR. 2011;60:1650-1653.
Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011 Dec 8. 365(23):2155-66. [Medline].
Extensively Drug-Resistant Tuberculosis (XDR TB). Centers for Disease Control and Prevention. Available at http://www.cdc.gov/tb/publications/factsheets/drtb/xdrtb.htm. Accessed: November 7, 2012.
Asensio JA, Arbues A, Perez E, Gicquel B, Martin C. Live tuberculosis vaccines based on phoP mutants: a step towards clinical trials. Expert Opin Biol Ther. 2008 Feb. 8(2):201-11. [Medline].
Wells CD, Cegielski JP, Nelson LJ, et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis. 2007 Aug 15. 196 Suppl 1:S86-107. [Medline].
Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med. 2006 Aug 1. 174(3):331-8. [Medline].
WHO. Fact Sheet 104. World Health Organization. Available at http://www.who.int/mediacentre/factsheets/fs104/en/index.html. Accessed: October 13, 2010.
CDC. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force. MMWR Recomm Rep. 2009 Feb 13. 58:1-43. [Medline].
Drug-resistant tuberculosis. World Health Organization. Available at http://www.who.int/tb/challenges/mdr/tdrfaqs/en/index.html. Accessed: November 26, 2012.
Mlambo CK, Warren RM, Poswa X, Victor TC, Duse AG, Marais E. Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa. Int J Tuberc Lung Dis. 2008 Jan. 12(1):99-104. [Medline].
World Health Organization. Antituberculosis drug resistance in the world. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance WHO. Geneva. 2008. 1-120. [Full Text].
CDC. Trends in Tuberculosis – United States, 2011. Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6111a2.htm?s_cid=mm6111a2_w.
Sokolove PE, Lee BS, Krawczyk JA, et al. Implementation of an emergency department triage procedure for the detection and isolation of patients with active pulmonary tuberculosis. Ann Emerg Med. 2000 Apr. 35(4):327-36. [Medline].
Moran GJ, McCabe F, Morgan MT, Talan DA. Delayed recognition and infection control for tuberculosis patients in the emergency department. Ann Emerg Med. 1995 Sep. 26(3):290-5. [Medline].
Menzies D, Joshi R, Pai M. Risk of tuberculosis infection and disease associated with work in health care settings. Int J Tuberc Lung Dis. 2007 Jun. 11(6):593-605. [Medline].
Verhagen LM, van den Hof S, van Deutekom H, et al. Mycobacterial factors relevant for transmission of tuberculosis. J Infect Dis. 2011 May. 203(9):1249-55. [Medline].
Leung CC, Lam TH, Chan WM, et al. Lower risk of tuberculosis in obesity. Arch Intern Med. 2007 Jun 25. 167(12):1297-304. [Medline].
Slama K, Chiang CY, Enarson DA, et al. Tobacco and tuberculosis: a qualitative systematic review and meta-analysis. Int J Tuberc Lung Dis. 2007 Oct. 11(10):1049-61. [Medline].
Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001 Oct 11. 345(15):1098-104. [Medline].
Brassard P, Suissa S, Kezouh A, Ernst P. Inhaled Corticosteroids and Risk of Tuberculosis in Patients with Respiratory Diseases. Am J Respir Crit Care Med. 2010 Oct 1. [Medline].
Bellamy R, Ruwende C, Corrah T, McAdam KP, Whittle HC, Hill AV. Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. N Engl J Med. 1998 Mar 5. 338(10):640-4. [Medline].
Cervino AC, Lakiss S, Sow O, Hill AV. Allelic association between the NRAMP1 gene and susceptibility to tuberculosis in Guinea-Conakry. Ann Hum Genet. 2000 Nov. 64:507-12. [Medline].
Searle S, Blackwell JM. Evidence for a functional repeat polymorphism in the promoter of the human NRAMP1 gene that correlates with autoimmune versus infectious disease susceptibility. J Med Genet. 1999 Apr. 36(4):295-9. [Medline]. [Full Text].
Tosh K, Campbell SJ, Fielding K, et al. Variants in the SP110 gene are associated with genetic susceptibility to tuberculosis in West Africa. Proc Natl Acad Sci U S A. 2006 Jul 5. 103(27):10364-8. [Medline]. [Full Text].
Khor CC, Vannberg FO, Chapman SJ, et al. CISH and susceptibility to infectious diseases. N Engl J Med. 2010 Jun 3. 362(22):2092-101. [Medline].
Intemann CD, Thye T, Niemann S, et al. Autophagy gene variant IRGM -261T contributes to protection from tuberculosis caused by Mycobacterium tuberculosis but not by M. africanum strains. PLoS Pathog. 2009 Sep. 5(9):e1000577. [Medline]. [Full Text].
Rossouw M, Nel HJ, Cooke GS, van Helden PD, Hoal EG. Association between tuberculosis and a polymorphic NFkappaB binding site in the interferon gamma gene. Lancet. 2003 May 31. 361(9372):1871-2. [Medline].
Levin M, Newport MJ, D'Souza S, et al. Familial disseminated atypical mycobacterial infection in childhood: a human mycobacterial susceptibility gene?. Lancet. 1995 Jan 14. 345(8942):79-83. [Medline].
Newport MJ, Huxley CM, Huston S, et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med. 1996 Dec 26. 335(26):1941-9. [Medline].
Khor CC, Chapman SJ, Vannberg FO, et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet. 2007 Apr. 39(4):523-8. [Medline]. [Full Text].
CDC. Tuberculosis (TB). Data and Statistics. Available at http://www.cdc.gov/tb/statistics/default.htm. Accessed: June 7, 2012.
WHO. Global tuberulosis control 2008: surveillance, planning, financing. World Health Organization. Available at http://www.who.int/topics/tuberculosis/en/. Accessed: October 13, 2010.
Jasmer RM, Bozeman L, Schwartzman K, et al. Recurrent tuberculosis in the United States and Canada: relapse or reinfection?. Am J Respir Crit Care Med. 2004 Dec 15. 170(12):1360-6. [Medline].
van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med. 1999 Oct 14. 341(16):1174-9. [Medline].
Waitt CJ, Peter K Banda N, White SA, et al. Early deaths during tuberculosis treatment are associated with depressed innate responses, bacterial infection, and tuberculosis progression. J Infect Dis. 2011 Aug. 204(3):358-62. [Medline]. [Full Text].
Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep. 2005 Dec 16. 54:49-55. [Medline].
Ang M, Htoon HM, Chee SP. Diagnosis of tuberculous uveitis: clinical application of an interferon-gamma release assay. Ophthalmology. 2009 Jul. 116(7):1391-6. [Medline].
Schuurmans MM, Ellmann A, Bouma H, Diacon AH, Dyckmans K, Bolliger CT. Solitary pulmonary nodule evaluation with 99mTc-methoxy isobutyl isonitrile in a tuberculosis-endemic area. Eur Respir J. 2007 Dec. 30(6):1090-5. [Medline].
Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis. 2005 Jan 15. 191(2):150-8. [Medline].
Muga R, Ferreros I, Langohr K, et al. Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART. AIDS. 2007 Nov 30. 21(18):2521-7. [Medline].
Sterling TR, Lau B, Zhang J, et al. Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening. J Infect Dis. 2011 Sep. 204(6):893-901. [Medline]. [Full Text].
Bassett IV, Wang B, Chetty S, et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis. 2010 Oct 1. 51(7):823-9. [Medline].
[Guideline] Jensen PA, Lambert LA, Iademarco MF, Ridzon R. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep. 2005 Dec 30. 54:1-141. [Medline].
Brown M, Varia H, Bassett P, Davidson RN, Wall R, Pasvol G. Prospective study of sputum induction, gastric washing, and bronchoalveolar lavage for the diagnosis of pulmonary tuberculosis in patients who are unable to expectorate. Clin Infect Dis. 2007 Jun 1. 44(11):1415-20. [Medline].
Jafari C, Thijsen S, Sotgiu G, et al. Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trialsgroup study. Am J Respir Crit Care Med. 2009 Oct 1. 180(7):666-73. [Medline]. [Full Text].
Tan SH, Tan BH, Goh CL, et al. Detection of Mycobacterium tuberculosis DNA using polymerase chain reaction in cutaneous tuberculosis and tuberculids. Int J Dermatol. 1999 Feb. 38(2):122-7. [Medline].
Vieites B, Suarez-Penaranda JM, Perez Del Molino ML, et al. Recovery of Mycobacterium tuberculosis DNA in biopsies of erythema induratum--results in a series of patients using an improved polymerase chain reaction technique. Br J Dermatol. 2005 Jun. 152(6):1394-6. [Medline].
[Guideline] Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep. 2009 Jan 16. 58(1):7-10. [Medline].
Reuters Health Information. Direct nucleic acid amplification testing improves TB diagnosis. Medscape Medical News. June 6, 2013. [Full Text].
Marks SM, Cronin W, Venkatappa T, et al. The Health-System Benefits and Cost-effectiveness of Using Mycobacterium Tuberculosis Direct Nucleic Acid Amplification Testing to Diagnose Tuberculosis Disease in the United States. Clin Infect Dis. 2013 May 22. [Medline].
Badak FZ, Kiska DL, Setterquist S, et al. Comparison of mycobacteria growth indicator tube with BACTEC 460 for detection and recovery of mycobacteria from clinical specimens. J Clin Microbiol. 1996 Sep. 34(9):2236-9. [Medline]. [Full Text].
Choi JH, Lee KW, Kang HR, et al. Clinical efficacy of direct DNA sequencing analysis on sputum specimens for early detection of drug-resistant Mycobacterium tuberculosis in a clinical setting. Chest. 2010 Feb. 137(2):393-400. [Medline].
Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011 Apr 30. 377(9776):1495-505. [Medline].
Minion J, Leung E, Menzies D, Pai M. Microscopic-observation drug susceptibility and thin layer agar assays for the detection of drug resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2010 Oct. 10(10):688-98. [Medline].
CDC. Classification of Tuberculin Skin Reactions. Available at http://www.cdc.gov/tb/publications/LTBI/diagnosis.htm#3. Accessed: June 11, 2012.
[Guideline] Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep. 2010 Jun 25. 59:1-25. [Medline].
Manuel O, Humar A, Preiksaitis J, et al. Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant. 2007 Dec. 7(12):2797-801. [Medline].
Mazurek GH, Weis SE, Moonan PK, et al. Prospective comparison of the tuberculin skin test and 2 whole-blood interferon-gamma release assays in persons with suspected tuberculosis. Clin Infect Dis. 2007 Oct 1. 45(7):837-45. [Medline].
Chang KC, Leung CC. Systematic review of interferon-gamma release assays in tuberculosis: focus on likelihood ratios. Thorax. 2010 Mar. 65(3):271-6. [Medline].
Leung CC, Yam WC, Yew WW, et al. T-Spot.TB outperforms tuberculin skin test in predicting tuberculosis disease. Am J Respir Crit Care Med. 2010 Sep 15. 182(6):834-40. [Medline].
Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A. Negative and positive predictive value of a whole-blood interferon-? release assay for developing active tuberculosis: an update. Am J Respir Crit Care Med. 2011 Jan 1. 183(1):88-95. [Medline].
Kim SH, Lee SO, Park JB, et al. A prospective longitudinal study evaluating the usefulness of a T-cell-based assay for latent tuberculosis infection in kidney transplant recipients. Am J Transplant. 2011 Sep. 11(9):1927-35. [Medline].
Lin HC, Lin HC, Chen SF. Increased risk of low birthweight and small for gestational age infants among women with tuberculosis. BJOG. 2010 Apr. 117(5):585-90. [Medline].
Sirturo (bedaquiline) prescribing information [package insert]. Titusville, NJ: Janssen Therapeutics, Division of Johnson & Johnson. December, 2012. Available at [Full Text].
Tucker ME. FDA approves bedaquiline for resistant TB treatment. Medscape Medical News. Dec 31, 2012. Available at http://www.medscape.com/viewarticle/776901. Accessed: January 8, 2013.
Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009 Jun 4. 360(23):2397-405. [Medline].
CDC. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR Recomm Rep. 2013 Oct 25. 62:1-12. [Medline].
Barclay L. MDR TB: CDC Issues Guidelines for Use of New Drug. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/813151. Accessed: October 28, 2013.
Kurbatova EV, Cavanaugh JS, Dalton T, Click E, Cegielski JP. Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009. Clin Infect Dis. 2013 Jul 9. [Medline].
Boggs W. Increasing Prevalence of Pyrazinamide-Resistant Tuberculosis. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/808192. Accessed: July 29, 2013.
Sanofi Receives FDA Approval of Priftin® (Rifapentine) Tablets for the Treatment of Latent Tuberculosis Infection. Available at http://en.sanofi.com/Images/37707_20141202_priftin_en.pdf. Accessed: Dec 10 2014.
Becerra MC, Appleton SC, Franke MF, et al. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet. 2011 Jan 8. 377(9760):147-52. [Medline].
Ayieko J, Abuogi L, Simchowitz B, Bukusi EA, Smith AH, Reingold A. Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: a meta-analysis. BMC Infect Dis. 2014 Feb 20. 14:91. [Medline]. [Full Text].
Hackethal V. Short TB Therapies Fail in Larger, Longer Trials. Medscape Medical News. Available at http://www.medscape.com/viewarticle/833799. Accessed: October 25, 2014.
Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014 Oct 23. 371(17):1588-98. [Medline].
Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014 Oct 23. 371(17):1599-608. [Medline].
Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014 Oct 23. 371(17):1577-87. [Medline].
Warner DF, Mizrahi V. Shortening treatment for tuberculosis--to basics. N Engl J Med. 2014 Oct 23. 371(17):1642-3. [Medline].
Xu P, Chen H, Xu J, Wu M, Zhu X, Wang F, et al. Moxifloxacin is an effective and safe candidate agent for the tuberculosis treatment: a meta-analysis. Int J Infect Dis. 2015 Oct 16. [Medline].